|
8:00 - 8:30
|
Registration and Breakfast
|
|
8:30- 8:35
|
Welcome and Opening Remarks Leslie Cho
|
|
8:35
|
Understanding the Role of Lp(a) as a CV Risk Marker to Therapeutic Target in the Prevention of CV Disease
Leslie Cho
|
|
8:55
|
Modern Lipid Management: New Goals, When to Treat, and New Therapies
Ashish Sarraju
|
|
9:15
|
GLP-1 Receptor Agonists and SGLT2 Inhibitors for Type 2 Diabetes and cardiorenal risk: New Insights and New Therapies
Dennis Bruemmer
|
|
9:35
|
Hypertension: New Drugs and Devices for Personalized Treatment
Luke Laffin
|
|
9:55
|
Hormone replacement and the heart: Estrogen and Testosterone
Leslie Cho
|
|
10:15
|
Break (10 mins)
|
|
10:25
|
Who Should Get a CAC? How Often? How to Use the Results to Asses Risk?
Ashish Sarraju
|
|
10:45
|
Dietary and Lifestyle Modifications to Reduce CV Risk
All faculty
Facilitator: Leslie Cho
|
|
11:05
|
Is it Time to Compare High-Intensity Pharmacotherapy to Surgery for the Management of Obesity Outcomes?
Dennis Bruemmer
|
|
11: 25
|
The Role of Digital Health & Technology including CGM in Cardiometabolic Risk Reduction
Ashish Sarraju
|
|
11: 45
|
Late-Breaking and Ongoing Trials in Cardiometabolic Medicine in 2023-2024
Luke Laffin
|
|
12:00
|
Interventional and Surgical Options and Outcomes When Prevention Falls Short
Leslie Cho
|
|
12:10
|
Audience Q&A
|
|
12:30
|
Adjourn
|
